Cargando…
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Non-small cell lung cancer is one of the most common types of malignances worldwide and the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical resection, chemotherapy, radiotherapy, and targeted therapy, with poor therapeutic effectiveness. In recent years, immune...
Autores principales: | Tang, Shengjie, Qin, Chao, Hu, Haiyang, Liu, Tao, He, Yiwei, Guo, Haiyang, Yan, Hang, Zhang, Jun, Tang, Shoujun, Zhou, Haining |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834198/ https://www.ncbi.nlm.nih.gov/pubmed/35159131 http://dx.doi.org/10.3390/cells11030320 |
Ejemplares similares
-
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
por: Guo, Haiyang, et al.
Publicado: (2022) -
miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential
por: Yan, Hang, et al.
Publicado: (2022) -
Development and validation of a novel prognostic model for patients with surgically resected esophageal squamous cell carcinoma
por: Hu, Haiyang, et al.
Publicado: (2022) -
Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis
por: Chen, Piaohong, et al.
Publicado: (2023) -
Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges
por: Regzedmaa, Orgilmaa, et al.
Publicado: (2019)